July 10, 2018 Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERα Wild-Type and Mutant Breast Cancer Models Next-generation endocrine therapy exhibits differentiated mechanism of action versus standard-of-care therapies and potently inhibits the ERα pathway H3 Biomedicine’s first… Read More